Recent data obtained from two next-generation sequencing (NGS) studies revealed that RMS harbor a high rate of recurrent mutations in the RAS pathway (3, 4).Whole-genome and whole-exome sequencing of 147 tumor/normal pairs showed recurrent alterations in the RAS genes predominantly in the ERMS subtype, i.e., NRAS in 11.7%, KRAS in 6.4%, and HRAS in 4.3% of cases (4). Here, KRAS is linked to neoplasm.